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Many neurodegenerative diseases are associated with deposits of aggregated protein in the brain.
The molecular pathways through which soluble proteins misfold to form amyloids and large protein
aggregates often include diverse oligomeric species, only some of which progress to the amyloid
state. Here we show that preﬁbrillar huntingtin (HTT) oligomers, isolated from Huntington’s disease
(HD) affected human brain samples or mouse models, stimulate polyglutamine amyloid formation.
Fibrillar HTT oligomers have been shown to be unstable under denaturing conditions and appear
not to lead to amyloid formation. Here we show that preﬁbrillar HTT oligomers are remarkably
stable and are potent seeds of polyglutamine amyloid formation. Therefore, our ﬁndings help to dis-
sect the complex molecular pathway of HTT misfolding.
 2015 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Huntington’s disease (HD) is an autosomal-dominant, neurode-
generative disorder caused by an expansion of CAG repeats in the
huntingtin (HTT) gene [1]. An invariably fatal disorder, HD is char-
acterized by involuntary movement, behavioral abnormalities, and
progressive decline in cognitive function. One of the salient fea-
tures of HD brain pathology is the presence of neuronal intranu-
clear and perinuclear inclusions, which are primarily composed
of an N-terminal proteolytic fragment of the huntingtin (HTT) pro-
tein [2]. Transgenic mouse models have been developed to emulate
the pathogenesis of HD, thus enabling investigation of the molecu-
lar species associated with neurodegeneration resulting from
expression of disease-related HTT and HTT fragments [3].
The roles of protein misfolding and inclusion formation in HD
pathogenesis have been controversial: some studies provide evi-
dence for the protein misfolding process that leads to inclusions
as a central event in pathogenesis [2,4–7], while others suggestthat large inclusions are neuroprotective [8,9]. Heterogeneous oli-
gomeric intermediates form along the protein misfolding pathway
[10] and have been associated with toxicity [11–16]. For Ab, a pep-
tide found in amyloid plaques in the brains of patients with
Alzheimer’s disease, two different oligomeric conformations have
been isolated, both of which seed the propagation of their own oli-
gomeric strains [17,18]. In another study, preﬁbrillar Ab oligomers
were shown to act as seeds for amyloid formation [19]. Which oli-
gomeric conformations of HTT are on the amyloid formation path-
way is less well deﬁned.
We recently developed and applied a seeding assay to detect
the presence of misfolded HTT in biological samples [20]. This
assay relied upon the propensity of pathological protein conforma-
tions to accelerate the conversion of monomeric proteins into amy-
loid, a process which can be monitored using the ﬂuorescent dye
Thioﬂavin T. Similar assays have been developed for the detection
of prions [21,22] and Ab [24,46]. When applied to drosophila
models of HD, seeding potency correlated well with toxicity [25].
Here, we demonstrate that preﬁbrillar HTT oligomers isolated from
two HD mouse models (Table 1) and human HD brain homoge-
nates by immunopuriﬁcation with the oligomer-speciﬁc antibody
A11, seed polyglutamine amyloid formation. These HTT oligomeric
species have strong seeding potency compared to the seeding
activity of HTT conformations immunopuriﬁed using a panel of
antibodies recognizing different epitopes within the HTT protein
(see Table 2).
Table 1
Mouse models used in this study.
Mouse model PolyQ length Protein context References
R6/2 >180 Exon1 product [34]
YAC128 128 Full HTT product [43]
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We puriﬁed misfolded HTT from crude brain homogenates
using magnetic bead-assisted immunopuriﬁcation to test for amy-
loid seeding activity (Fig. 1A). Magnetic beads labeled with the
MW8 antibody [26] were incubated with clariﬁed brain homoge-
nates of end-stage R6/2 mice (or age matched WT controls), cap-
tured with a magnet, and rinsed. The beads were incubated with
6 M GdnHCl to elute HTT, and the spent magnetic beads were
removed with a magnet. Misfolded HTT has been shown to be
stable in these denaturing conditions [27]. The eluent was incu-
bated with a solution of monomeric K2Q44K2 peptide and amyloid
formation kinetics were monitored with Thioﬂavin T (ThT) ﬂuores-
cence. The solution containing eluent from beads which had been
incubated with R6/2 brain homogenate formed amyloid more
rapidly than that with control eluent (Fig. 1B). To simplify kinetic
data analysis throughout this report, we quantiﬁed ThT ﬂuores-
cence at a time point just after the control samples began to spon-
taneously form amyloid, which we called t1.2 (deﬁned in Methods
and indicated by the dashed line in Fig. 1B). At this time, ThT ﬂuo-
rescence was signiﬁcantly (P < 0.001) higher for samples contain-
ing R6/2 HTT extracts compared to control (Fig. 1B).
Incubation of R6/2 brain homogenates with beads labeled with
9E10 antibody, which is speciﬁc for c-myc and does not recognizeTable 2
Primary antibodies used to immunopurify HTT from HD brain homogenates.
Antibody Epitope References
A11 Protein oligomers [28]
MW8 AEEPLHRP after polyglutamine stretch [26]
3B5H10 Polyglutamine [14]
mEM48 PPGPAVA after polyglutamine stretch [44]
H7540 N-terminal residues 3–16 of human HTT Sigma–Aldrich
Fig. 1. Immunopuriﬁed HTT from R6/2 mouse brain tissue accelerates conversion of poly
for conformational selection of HTT protein and determination of seeding activity. In brie
speciﬁc antibodies, followed by separation of the magnetic beads from the tissue supe
seeding activity after elution from the antibodies in 6 M GdnHCl. (B) Amyloid formation
HTT from R6/2 and wild type control brain homogenate immunopuriﬁed with MW8. Acce
compared to control samples. Accelerated conversion of polyglutamine into amyloid wa
the control sample (t1.2 indicated on graph). (C) No signiﬁcant increase in ThT ﬂuorescen
Ab), was used in the immunopuriﬁcation step. Error bars denote standard error (N = 4 iHTT, resulted in no increase in ThT intensity at t1.2 when added to
amyloid formation reactions (Fig. 1C). Similarly, elimination of the
primary antibody in the immunopuriﬁcation protocol led to a loss
of signal in the seeding assay (Fig. 1C). The direct addition of the
magnetic beads containing HTT immunopuriﬁed from R6/2 brain
tissue also accelerated amyloid formation (SI Fig. 1), however the
discrimination between positive and negative samples was not as
pronounced as that observed following elution with GdnHCl, and
thus elution was used for all subsequent experiments.
We applied the same immunopuriﬁcation and seeding tech-
nique using A11, an antibody that is speciﬁc for oligomeric protein
species and does not bind to monomeric or amyloid protein confor-
mations [28]. Brain homogenates from three different sources (end
stage R6/2, YAC128, and human HD) or appropriate negative con-
trol sources were incubated with A11-labeled beads, and the elu-
ent was added to amyloid formation reactions. The ThT
ﬂuorescence signal at t1.2 was signiﬁcantly higher for eluent
derived from disease brain compared to wild-type mouse and nor-
mal (non-HD) human control brain samples (Fig. 2A, P < 0.001,
N = 3 brains of each type).
The limit of detection for misfolded HTT in the R6/2 model was
determined by gradually reducing the amount of brain homoge-
nate used per experiment while keeping the quantity of A11 anti-
body the same (Fig. 2B). Seeding activity of A11-puriﬁed HTT
oligomers was observed with as little as 0.02 mg of R6/2 brain tis-
sue equivalent. Use of the immunopuriﬁcation method described
here with the seeding assay did not signiﬁcantly alter the limit of
detection compared to the original protocol, which relied on
sucrose gradient puriﬁcation method [20,36].
Immunogold-EM was used to conﬁrm that A11 immunopuriﬁes
oligomeric species from brain homogenate. The eluent from A11
labeled beads incubated with brain homogenates from R6/2 mice,
YAC128 mice, and human HD samples had small EM48-positive
aggregates in the size range of 20–70 nm (Fig. 2C). The character-
istics of oligomers observed were comparable to those reported
by others for HTT oligomers [30–33]. Eluents from control brain
homogenate samples had only monomeric immunoreactivity, as
identiﬁed by the lack of clustering gold particles, while eluents
immunopuriﬁed with the MW8 antibody recognizing HTT con-
tained large aggregates (Fig. 2C).glutamine peptides into amyloid. (A) Schematic of the experimental approach used
f, clariﬁed brain homogenate was incubated with magnetic beads coated with HTT-
rnatant in a magnetic ﬁeld. The puriﬁed HTT protein was then tested for amyloid
kinetics were measured in a buffered solution of K2Q44K2 peptide containing eluted
lerated amyloid formation was observed by ThT ﬂuorescence for R6/2 brain samples
s quantiﬁed using the measurement observed just after the end of the lag phase for
ce was observed when a negative control antibody (9E10), or no antibody at all (No
ndependent measurements for each sample; ***P < 0.001).
Fig. 2. Preﬁbrilar huntingtin oligomers isolated with A11 antibody are potent seeds of amyloid formation. (A) An oligomer-speciﬁc antibody, A11, was used to immunopurify
misfolded HTT protein from end-stage R6/2 and YAC128 mouse brains as well as human HD brain tissue. Puriﬁed HTT oligomers signiﬁcantly accelerated polyglutamine
amyloid conversion compared to appropriate negative controls for each brain type, based on ThT ﬂuorescence at time t1.2 (N = 3 brains of each type, N = 4 independent
measurements for each sample). (B) Seeding activity with the A11-puriﬁed HTT oligomers, shown as a function of brain tissue quantity equivalent subject to puriﬁcation. (C)
Electron micrographs of HTT immunopuriﬁed from brain homogenates using oligomer-speciﬁc antibody compared to HTT-speciﬁc antibody. HTT from indicated HD brain
homogenates or controls (N = 3 brains for each sample type) were immunopuriﬁed with either A11-coated or MW8-coated magnetic beads, eluted, and then labeled for HTT
with 10-nm immunogold. Error bars denote standard error. Scale bar represents 200 nm.
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ies that target a range of HTT epitopes (Table 2) were also tested.
Beads labeled with each of the antibodies were incubated with
HD brain homogenates or controls (N = 3 brains of each type).
For R6/2 mice, all anti-HTT antibodies tested captured amyloido-
genic HTT, resulting in higher ThT ﬂuorescence compared to con-
trol (Fig. 3, P < 0.01). For YAC128 mice, MW8 and H7540 did not
capture amyloidogenic HTT in comparison to control samples,
while 3B5H10 and EM48 eluents were signiﬁcantly more amy-
loidogenic compared to WT controls (P < 0.05). In postmortem
human HD tissue samples, H7540, MW8, and mEM48 antibodies
captured amyloidogenic HTT while 3B5H10 did not (Fig. 3,
P < 0.05).
We compared the efﬁciency of HTT immunopuriﬁcation with
A11 to 3B5H10 using Western blots. A single reaction-equivalent
of brain homogenate was subjected to immunopuriﬁcation from
wild-type (FVB) and YAC128 mouse brain (Fig. 4). Most of the
HTT protein isolated from YAC128 brain homogenate was
SDS-insoluble and did not penetrate the gel, complicating quantiﬁ-
cation. For both FVB and YAC128 mouse brains, immunopuriﬁca-
tion with the A11 antibody isolated very little HTT compared to
that isolated with 3B5H10.
3. Discussion
Previously, we developed an amyloid seeding assay for the sensi-
tive detection of misfolded HTT in brain tissue samples from HD
mouse models and from human HD patients [20]. In the original
assay,wepuriﬁedmisfoldedHTT frombrain tissueby several rounds
of high-speedcentrifugation in thepresenceof detergents; however,
this biochemical puriﬁcation step was cumbersome. Here we
demonstrate that the assay canbe simpliﬁedwith an immunopuriﬁ-
cation step to isolate HTT seeds. Combining immunopuriﬁcation
with amyloid seeding provided a convenient platform for probing
the exposed epitopes of amyloidogenic HTT protein from mouse
models andhumanHDbrain, aswell as testing the amyloidogenicity
of HTT oligomers isolated with the A11 antibody.
The ability to detect amyloidogenic HTT varied depending on
the tissue source (Fig. 2) as well as the antibody used for
immunopuriﬁcation (Fig. 3). The stronger seeding potential
observed for R6/2 mouse brain eluents compared to YAC128mouse and human HD brain eluents likely reﬂects overexpression
of HTT in the R6/2 model [34], while the YAC128 mouse line
expresses levels of the HTT protein equivalent to that found in
human brain. When 3B5H10 was used to immunopurify HTT from
YAC128 mouse and human HD brain homogenates, seeding was
observed only for the former. This may be attributable to the epi-
tope of 3B5H10, which recognizes polyglutamine repeats contain-
ing at least 10 residues. The presence of two available epitopes on a
single polypeptide separated by a sufﬁciently long linker results in
much tighter binding due to avidity [23,35]. Thus, the 3B5H10
antibody may be more efﬁcient when used to immunopurify HTT
from sources with very long polyglutamine stretches, such as
YAC128 mice, which express HTT containing 128 glutamines, than
from human brain tissue, which expresses HTT with only 40–45
glutamines.
Surprisingly, for human HD and YAC128 samples, preﬁbrillar
HTT oligomers isolated with A11 were robustly amyloidogenic,
while eluents obtained with antibodies speciﬁc for HTT were less
so. Qualitatively, we found that the amount of HTT immunopuri-
ﬁed from YAC128 brain tissue by A11 was much less than that
obtained using 3B5H10 (Fig. 4). This may reﬂect competition
between amyloidogenic and non-amyloidogenic HTT species for
antibody binding sites, or retardation of amyloid formation by
non-amyloidogenic HTT species, as the presence of protein gener-
ally inhibits K2Q44K2 amyloid formation in a non-speciﬁc fashion
[20].
Although quantiﬁcation of immunopuriﬁcation efﬁciency
would allow additional insights into the presence of distinct con-
formations of HTT in different animal models and their seeding
behavior, techniques to quantify mutant HTT in HD brain tissue
are lacking due to issues with solubility. To illustrate this point,
we attempted to compare the amount of HTT immunopuriﬁed
with A11 and 3B5H10 antibodies from wild type and YAC128
mouse brain homogenates by Western blot (Fig. 4). Insoluble HTT
protein in the YAC128 brain homogenates did not penetrate the
gel, as reported by others [11,29,36,37], allowing some aggregates
to be lost during the transfer to the blot. Although formic acid has
been suggested to dissolve HTT aggregates from transiently trans-
fected cell cultures, brain-derived aggregates have resisted formic
acid solubilization and penetration into the gel [11,42]. The ability
to quantify protein contained within aggregates is further limited
Fig. 3. Differential seeding of HTT isolated with a panel of antibodies from brains of
transgenic HD mouse models and from human HD brain tissue. HTT was
immunopuriﬁed from end stage R6/2 mice (A), end stage YAC128 mice (B), and
human HD (C) brain with a panel of antibodies (A11, MW8, 3B5H10, mEM48, and
H7540, described in Table 2). ThT signal at t1.2 is shown for each sample tested. For
R6/2 and YAC128 mice, age-matched WT controls were used. Bars denote standard
error (N = 4 independent measurements for each sample).
Fig. 4. Comparison of HTT immunopuriﬁcation products using oligomer-speciﬁc
and polyglutamine-speciﬁc antibodies. Western blots of HTT immunopuriﬁed from
wild-type and YAC128 mouse brain homogenates with A11, which recognizes
preﬁbrillar oligomers, and 3B5H10, which binds to polyglutamine. Aggregated HTT
is seen trapped in the well for the YAC128 mouse brain. The blots were probed with
3B5H10.
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large aggregates, or which are buried throughout in some
non-native conformations. These aggregates lack the 1:1 antibody
to epitope ratio on which quantiﬁcation by immunodetection
depends.
Oligomeric HTT species have been suggested to be a conforma-
tionally heterogeneous and dynamic population, with someconformations being non-amyloidogenic [10,32,38]. To determine
if preﬁbrillar oligomers could seed amyloid formation, misfolded
HTT was immunopuriﬁed with A11, a conformational antibody
that has been used for the detection of Ab oligomers, a-synuclein
oligomers, and HTT oligomers [28]. HTT conformations puriﬁed
with A11 were active seeds in the assay and could be detected with
a high level of statistical signiﬁcance (P < 0.01) for all brain tissue
types tested (Fig. 2). Additionally, these puriﬁed HTT oligomers
generally had equivalent or higher activity in the amyloid seeding
assay compared to HTT puriﬁed using other antibodies (Fig. 3).
Immunogold EM was used to conﬁrm that A11 immunopuriﬁed
HTT oligomers (Fig. 2C) with the same diameter size range of
20–70 nm as previously reported [30]. These results demonstrate
that oligomeric HTT species which are A11 reactive are potent
seeds for amyloid formation.
We observed signiﬁcant seeding with A11 eluents across all HD
sample sources studied, even after incubation in 6 M GndHCl,
which demonstrates that preﬁbrillar HTT oligomers remain intact
and retain their amyloid seeding activity under strongly denatur-
ing conditions. Fully formed HTT amyloids are notoriously stable,
remaining insoluble in boiling SDS [45]; the observation that amy-
loidogenic oligomeric precursors share this biochemical feature
suggests a fundamental structural commonality. In contrast to pre-
ﬁbrillar HTT oligomers, ﬁbrillar HTT oligomers appear to be rela-
tively unstable and SDS-soluble [39]. Compounds which block
formation of ﬁbrillar HTT oligomers do not halt inclusion body for-
mation, suggesting ﬁbrillar HTT oligomers are off the amyloid for-
mation pathway [39]. The resilience of preﬁbrillar oligomers to
strong denaturing conditions suggests possible structural stabiliza-
tion by covalent bonds, as hypothesized to be present in HTT amy-
loids [27], implying that such covalent bonds are an early step in
ﬁbril formation. With the exception of covalent bond formation,
the biochemical pathway which emerges for HTT misfolding
strongly resembles that of Ab, in which preﬁbrillar oligomers are
on the amyloid formation pathway [19], while ﬁbrillar oligomers
are not [18]. Such consistency in the underlying mechanism of pro-
tein misfolding is encouraging for the search for therapeutics
which may alter this process and halt neurodegeneration.
4. Materials and methods
The work described in this article has been carried out in accor-
dance with The Code of Ethics of the World Medical Association
(Declaration of Helsinki), EU Directive 2010/63/EU, and the
Uniform Requirements for manuscripts submitted to Biomedical
journals.
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All animal procedures performed were approved by the
Institutional Animal Care and Use Committee (IACUC) at the
University of Delaware. Transgenic mice (Jackson Labs), including
R6/2 (2810) and YAC128 (4938) were crossbred with correspond-
ing wild type mice to create hemizygous progeny. Genotypes were
conﬁrmed by PCR according to Jackson Labs protocols. R6/2 were
allowed to age until they exhibited behavioral symptoms of neu-
rodegeneration such as tremors, loss of balance, hind limb clasping,
and weight loss (11–13 weeks). YAC128 mice and controls were
sacriﬁced at 100–110 weeks. Mice were euthanized by CO2
asphyxiation, followed by removal of the brain. Whole brain tis-
sues were kept frozen at 80 C until used.
4.2. Human tissue samples
Human brain tissue samples were obtained from the Harvard
Brain Tissue Resource Center and Spinal Fluid Resource Center at
UCLA, including samples from the CAP (caudate, putamen and acu-
mens) region of HD affected patients with pathological classiﬁca-
tion HD grade II-IV and normal non-disease donor controls.
4.3. Preparation of brain homogenates
The whole mouse-brain tissue sample was thawed on ice and
suspended in 9 volumes of PBS buffer supplemented with protease
inhibitors (1 mM PMSF and protease inhibitor cocktail, P8340 from
Sigma). The brain sample was homogenized on ice by extrusion
through progressively thinner needles (10 passages each for 18
and 21 gauge). The brain homogenate was centrifuged (2000g,
5 min, 4 C) and the supernatant was saved. The residual pellet
was homogenized in 10 volumes of PBS buffer (with protease inhi-
bitors) by extrusion through a 21 gauge needle. This homogenate
was centrifuged (21000g, 5 min, 4 C) and the supernatant was
mixed with previously saved supernatant to yield a 5 wt% brain
homogenate. A small portion was further diluted 5-fold with PBS
buffer to 1 wt%. 250 lL of this sample (2.5 mg brain tissue equiva-
lent) were used for incubation with magnetic beads labeled with
primary antibody as described above. Alternately, 5 wt% brain
homogenate was prepared in a homogenization buffer (10 mM
Tris, 1 mM EDTA, 0.8 M NaCl, 10% sucrose and 0.1% triton X-100),
mixed with 0.25 volume of 1 M tris solution (pH 8.0) and 3.75 vol-
umes of water to reduce the salt concentration. This resulted in
1 wt% brain homogenate that was further extruded through a 21
gauge needle before incubation.
4.4. Magnetic bead-assisted immunopuriﬁcation of misfolded HTT
from brain homogenates
Magnetic beads and monoclonal/polyclonal antibodies were
obtained from commercial sources as follows: anti-mouse IgG
magnetic beads (S1431S, NEB), anti-rabbit IgG magnetic beads
(S1432S, NEB), MW8 (Developmental studies hybridoma bank
(DSHB) at University of Iowa), anti-huntingtin N-terminal
(H7540, Sigma Aldrich), mEM48 (MAB5374, Millipore), 3B5H10
(P1874, Sigma Aldrich), A11 (AHB0052, Invitrogen), 9E10 (DSHB).
Twenty microliters of magnetic beads (binding capacity 2 lg)
conjugated to anti-mouse (or anti-rabbit) IgG secondary antibodies
were washed with PBS buffer and incubated with a solution of 1 lg
of primary antibody indicated in 200 lL of 0.1% BSA in PBS buffer at
room temperature with continuous shaking at low speed. After 2 h
of incubation, magnetic beads were removed and washed 3 times
with PBST buffer. If more than one set of samples were used, the
amount of magnetic beads was scaled up as desired to ensure sam-
ple homogeneity. Magnetic beads were divided into two aliquots(10 lg bead equivalent) and each was incubated separately either
with HD-positive or control brain homogenate samples, which
were prepared as given below.
After 2 h of incubation at room temperature with continuous
slow shaking, magnetic beads were removed and washed three
times with TBST or PBST and one time with TBS or PBS. If the beads
were used directly for the seeding assay, they were suspended in
500 lL of TBS buffer and used as seed solution for the seeding
assay as described. Else, the beads were incubated with 50 lL of
6 M GdnHCl solution at room temperature. After 1 h of shaking
at medium speed, the suspension was diluted with 450 lL of TBS
buffer and vigorously mixed by vortexing. At this stage, the beads
were removed from the suspension and the eluent was used as the
seed in the seeding assay.
4.5. Peptide solubilization
To create monomeric solutions of K2Q44K2 (Keck Biotechnology
Center at Yale University, >90% purity by HPLC), we used a previ-
ously reported protocol [40,41] with a slight modiﬁcation. Brieﬂy,
peptide powder was resuspended overnight with constant stirring
to 2 mg/mL in a 1:1 mixture of triﬂuoroacetic acid (TFA) and hex-
aﬂuoroisopropanol (HFIP) in a covered glass vial. Solvent was
removed under argon ﬂow and the peptide ﬁlm was immediately
dissolved to 2 mg/mL monomeric peptide in a 2 M GdnHCl solu-
tion. The peptide solution was then spun in the ultracentrifuge at
300000g for 3 h and the monomeric peptide was recovered from
the top 3=4 of the solution in the tube. The disaggregated peptide
was then aliquoted into 1 mL fractions, and stored at 80 C until
needed for the experiment.
4.6. Monitoring amyloid formation with Thioﬂavin T
Disaggregated monomer peptide was diluted with TBS pH 8.5
and 100 lM ThT (T3516, Sigma) to a peptide concentration of
0.4 mg/mL. This solution was mixed with an equal volume of the
seeding agent solution, containing an indicated amount of partially
misfolded HTT from brain tissues, and transferred to 4 wells of an
opaque 96-well ﬂat bottom plate (353945, BD biosciences), con-
taining a single 3 mm glass bead (z143928, Sigma) for mixing.
Each well contained 200 lL of 0.2 mg/mL of peptide, 50 lM ThT,
and 0.5 M GdnHCl (0.2 M GdnHCl if beads were used without elu-
tion) in TBS buffer pH 8 at an indicated concentration of amyloid
seeds. The plate was sealed with a sealing tape (235207, Fisher)
and incubated in a SpectramaxM2 plate reader at 37 C, with shak-
ing for 5 s every 5 min. Fluorescence intensity was recorded every
5 min with excitation at 444 nm and emission at 484 nm.
Background ﬂuorescence recorded of the solution in the absence
of peptide was subtracted from each dataset.
4.7. Immunogold-electron microscopy
Morphology of protein species isolated from control and HD
mouse model and HD human brain tissue preparations were
detected with immunogold particles with electron microscopy, fol-
lowing a previously described method [30]. 5 lL of eluted material
captured from brain homogenate by antibody-coated magnetic
beads were transferred to a freshly glow-discharged 300-mesh
carbon-coated EM grids (Electron Microscopy Sciences) and incu-
bated at room temperature for 1 min. Excess solution was removed
with ﬁlter paper and the grid was allowed to air-dry for 5 min. The
gridswere then blockedwith blocking solution (0.1% BSA in PBS) for
15 min and then transferred to a solution ofMW8primary antibody
(for anti-rabbit immunopuriﬁcation) or mEM40 primary antibody
(for anti-mouse immunopuriﬁcation), diluted 1:100 in blocking
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times in a drop of blocking buffer, supplemented with 0.1%
Tween-20 (2 min/drop), and 2 times in water. The grids were then
transferred to an anti-mouse or anti-rabbit secondary antibody con-
jugated with 10-nm colloidal gold particles (Electron Microscopy
Sciences), diluted 1:200 in blocking solution for 1 h. The grids were
washed (6 times in PBS, 2 times in water, 2 min each) and air-dried
for 10 min. Staining was performed by adding 3 lL of 1% phospho-
tungstic acid for 20 s. Excess stain was removed with ﬁlter paper
and the grids were allowed to air-dry. Images were taken with a
transmission electron microscopy (Tecnai 12 Biotwin) at 120 V.
4.8. Western blot
Immunopuriﬁed HTT from partially puriﬁed brain homogenate
(0.5 mg) was diluted 1:1 with 2xSDS loading buffer (4% SDS, 20%
glycerol, 125 mMTris, 0.1% b-mercaptoethanol, 0.02% bromophenol
blue), boiled for 5 min, and subjected to SDS–PAGE analysis on 4–
20% polyacrylamide gels (Pierce) in Tris-HEPES-SDS buffer (Pierce)
at 150 V for 30 min. Proteins were blotted to a nitrocellulose mem-
brane in transfer buffer (50 mM Tris, 390 mM glycine, 0.05% SDS,
10% ethanol) at 25 V for 45 min. Immunoblots were blocked with
1% non-fat drymilk in PBS for 2 h, probedwith the 3B5H10 antibody
(diluted 1:1000; P1874, SigmaAldrich), and amouse secondaryHRP
antibody (Invitrogen). Protein content was detected with chemilu-
minescence using SuperSignal West Dura substrate (Pierce).
4.9. Data analysis
To calculate the lag phase ‘‘t’’ for ThT kinetic data, we identiﬁed
the ﬁrst of 3 consecutive time points that were signiﬁcantly
(P < 103) above the background and after which the signal did
not fall below background. To plot the ThT ﬂuorescence values as
a function of antibodies on the same graph, we calculated an aver-
age of 4 time point ﬂuorescence values centered at time point
t1.2 = 1.2  t for WT or normal sample. Each biological replicate
data point is represented by an average of 4 wells, each with
0.5-mg tissue equivalent per well, unless otherwise stated. P values
were calculated by 2-sample student’s t-tests by using Minitab 16
software (Minitab, State College, PA).
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